BioNTech to start work on first African mRNA vaccine factory this month
The Rwanda site will be the first piece of the company’s African manufacturing network
BioNTech has said the construction of a factory to produce mRNA COVID-19 vaccines will begin on June 23 in Rwanda, marking the first step in the company’s plans to build an African manufacturing network.
The German biotech said in a statement on Thursday that the facility’s ground-breaking ceremony in Kigali will be attended by Rwandan President Paul Kagame, other heads of African states, as well as representatives from the European Union and the World Health Organization.
BioNTech’s Comirnaty-branded vaccine was developed with US partner Pfizer and is now the most widely used in the world. The company plans to establish scalable vaccine production on the continent by developing and delivering turnkey mRNA manufacturing facilities based on a container solution dubbed ‘BioNTainer’. It plans to deliver its BioNTainer modules to the Rwanda site by the end of 2022 and also expects deliveries to Senegal and potentially South Africa.
The manufacturing solution consists of one drug substance and one formulation module, each called a BioNTainer. Each module is built of six ISO sized containers, allowing for mRNA vaccine production in bulk (mRNA manufacturing and formulation). Fill-and-finish will be taken over by local partners.
The company says each BioNTainer offers an estimated initial capacity of up to 50 million doses per year. It also notes that BioNTainers could make other mRNA vaccines against malaria or tuberculosis, depending on product development progress and future public-health priorities.
The project comes as Western-made coronavirus vaccine doses become more widely available in Africa, with South Africa’s Aspen Pharmacare striking a deal to manufacture Johnson & Johnson's vaccine earlier this year. Africa has also received a significant number of COVAX doses, with the continent representing 45% of the alliance’s total donations (now more than 500 million).
There has been a push for investment in African manufacturing capacity as donations continue to be ad-hoc in nature and doses generally have short shelf lives. This makes it difficult to plan vaccination campaigns and achieve a higher rate of coverage.
However, misinformation around vaccine safety and a lack of urgency as the pandemic progresses have also impacted Africa’s vaccine rollout. According to the African CDC, just 17.3% of the population is fully vaccinated and only 71% of available doses have been utilised.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance